Get documents about "Topic
Document Sample
Topic Work Published/ Date of Referral Date of final Start of
programme ongoing marketing date (2) NICE NICE
(3)
authorisation guidance appraisal
(1)
Xolair (omalizumab) for 8 Published October April 2003 November November
uncontrolled asthma 2005 2007 2006
Remicade (infliximab) for 8 Published September April 2003 January March 2007
psoriasis 2005 2008
Natrecor (nesiritide) for heart 9 Ongoing n/a October n/a October
failure (acute 2003 2003
decompensated)
Erbitux (cetuximab) for head 10 Published March 2006 June 2004 June 2008 June 2006
and neck cancer
Iressa (gefitinib) for lung 10 Ongoing n/a June 2004 n/a January
cancer (non-small cell) - 2nd 2009
Line Use
Iressa (gefitinib) for non 10 Ongoing Expected June 2004 n/a June 09
small cell lung cancer (1st October
line use) 2009
Tysabri (natalizumab) for 10 Published June 2006 June 2004 August 2007 September
multiple sclerosis 2006
Alimta (pemetrexed) for 10 Published September June 2004 January April 2005
mesothelioma 2004 2008
Erbitux (cetuximab) for head 10 Published March 2006 June 2004 June 2008 June 2006
and neck cancer
Campto (irinotecan) for colon 10 Ongoing n/a June 2004 n/a n/a
cancer (adjuvant)
Mabthera (rituximab) for 11 Published August 2004 April 2005 February April 2007
untreated stage III or IV 2008
follicular lymphoma(4)
Taxol (paclitaxel) for early 11 Published March 2005 April 2005 September November
node-positive breast cancer 2006 2005
Taxotere (docetaxel) for 11 Published March 2006 April 2005 September November
early node-positive breast 2006 2005
cancer
Gemzar (gemcitabine) for 11 Published September April 2005 January February
metastatic breast cancer 2004 2007 2006
Fludara (fludarabine) for 11 Published February April 2005 February February
chronic lymphocytic 2003 2007 2006
leukaemia
Alimta (pemetrexed) for the 11 Published September April 2005 August 2007 April 2006
treatment of non-small cell 2004
lung cancer
Tarceva (erlotinib) for lung 11 Published September April 2005 November March 2006
cancer (non-small cell) 2005 2008
Idraparinux sodium for 12 Ongoing n/a July 2006 n/a July 2006
stroke (in patients with atrial
fibrillation)
Arava (leflunomide) for 12 Ongoing June 2004 July 2006 n/a July 2006
psoriatic arthritis (moderate
to severe)
Idraparinux sodium for 12 Ongoing n/a July 2006 n/a July 2006
venous thromboembolism
(recurrent)
Herceptin (trastuzumab) for 12 Published May 2006 July 2005 August 2006 December
early-stage HER2-positive 2005
breast cancer
Alteplase (actilyse) for the 12 Published June 2002 July 2006 June 2007 September
treatment of acute ischaemic 2006
stroke
Champix (varenicline) for 12 Published September July 2006 July 2007 November
smoking cessation 2006 2006
Humira (adalimumab) for the 12 Published August 2005 July 2005 August 2007 September
treatment of psoriatic 2006
arthritis
MabThera (rituximab) for the 12 Published July 2006 July 2005 August 2007 September
treatment of rheumatoid 2006
arthritis
Velcade (bortezomib) for 12 Published April 2004 July 2005 October December
multiple myeloma 2007 2005
Orencia (abatacept) for 12 Published May 2007 July 2006 April 2008 October
rheumatoid arthritis 2006
Tyverb (lapatinib) for breast 13 Ongoing June 2008 December n/a February
cancer (advanced or 2006 2007
metastatic)
Cimzia (certolizumab) for 13 Ongoing n/a December n/a December
rheumatoid arthritis 2006 2006
Remicade (infliximab) for 13 Published February December December March 2007
ulcerative colitis (acute 2006 2006 2008
exacerbations)
Remicade (infliximab) for 13 Published February December April 2008 March 2007
ulcerative colitis 2006 2006
Acomplia (rimonabant) for 13 Published June 2006 December June 2008 June 2007
obesity 2006
Baraclude (entecavir) for 14 Published June 2006 June 2007 August 2008 September
Hepatitis B 2007
Sebivo (telbivudine) for 14 Published April 2007 June 2007 August 2008 September
Hepatitis B 2007
Adenuric (febuxostat) for 14 Published April 2008 June 2007 December August 2007
hyperuricaemia 2008
Humira (adalimumab) for the 14 Published December June 2007 June 2008 July 2007
chronic psoriasis 2007
Ixabepilone for breast cancer 15 Ongoing n/a December n/a July 2008
(locally advanced or 2007
metastatic)
Erbitux (cetuximab) for 15 Ongoing July 2008 December n/a January
colorectal cancer (first line) 2007 2008
Erbitux (cetuximab) for lung 15 Ongoing n/a December n/a October
cancer (non-small cell) 2007 2008
Revlimid (lenalidomide) for 15 Ongoing June 2007 December n/a April 2008
multiple myeloma 2007
Xeloda (capectitabine) for 15 Ongoing n/a December n/a June 2009
pancreatic cancer 2007
Pradaxa (dabigatran) for 15 Published March 2008 December September January
venous thromboembolism 2007 2008 2008
Erbitux (cetuximab) for head 16 Ongoing March 2006 March n/a March 2008
and neck cancer (squamous 2008
cell carcinoma)
Effient (prasugrel) for acute 17 Ongoing n/a June 2008 n/a November
coronary artery syndrome 2008
Viread (tenofovir disoproxil 17 Ongoing April 2008 June 2008 n/a August 2008
fumarate) for Hepatitis B
Nexavar (sorafenib) for 17 Ongoing October June 2008 n/a August 2008
hepatocellular carcinoma 2007
(advanced and metastatic)
Orencia (abatacept) for 17 Ongoing May 2007 June 2008 n/a January
juvenile idiopathic arthritis 2009
Humira (adalimumab) for 17 Ongoing n/a June 2008 n/a September
juvenile idiopathic arthritis 2008
Sprycel (dasatinib) for 17 Ongoing November June 2008 n/a July 2008
leukaemia (acute 2006
lymphoblastic)
Temodal (temoazolomide) 17 Ongoing June 2005 June 2008 n/a March 2009
for melanoma (advanced and
metastatic
Mifamurtide for 17 Ongoing n/a June 2008 n/a August 2008
osteosarcoma
Romiplostim for 17 Ongoing n/a June 2008 n/a August 2008
thrombocytompenic pupura
Promacta (eltrombopag) for 17 Ongoing n/a June 2008 n/a March 2009
thrombocytopenic purpura
Xarelto (rivaroxaban) for 17 Published July 2008 June 2008 April 2009 August 2008
venous thromboembolism
Azacitidine for acute 18 Ongoing n/a July 2008 n/a January
myelomonocytic leukaemia 2009
and acute myeloid leukaemia
Xeloda (capecitabine) for 18 Ongoing January July 2008 n/a December
advanced gastric cancer 2008 2008
Relistor (methylnaltrexone) 18 Ongoing July 2008 July 2008 n/a February
for opioid-induced 2009
constipation in patients
receiving palliative care
Datiros (alitretinoin) for 18 Ongoing n/a July 2008 n/a October
severe chronic hand eczema 2008
Alimta (pemetrexed) for 18 Ongoing April 2008 July 2008 n/a June 2009
locally advanced or
metastatic non-small cell
lung cancer
Mabthera (rituximab) for 18 Ongoing n/a July 2008 n/a September
relapsed treatment of 2009
chronic lymphocytic
leukaemia
Mabthera (rituximab) for 18 Ongoing n/a July 2008 n/a September
chronic lymphocytic 2008
leukaemia (first line)
Sutent (sunitinib) for 18 Ongoing July 2006 July 2008 n/a August 2008
gastrointestinal stromal
tumours
Actemra (tocillizumab) for 18 Ongoing n/a July 2008 n/a November
rheumatoid arthritis 2008
Hycamtin (topotecan) for 18 Ongoing n/a July 2008 n/a December
carcinoma of the cervix 2008
Yondelis (trabectedin) for 18 Ongoing September July 2008 n/a September
advanced metastatic soft 2007 2008
tissue sarcoma
Ustekinumab for moderate to 18 Ongoing n/a July 2008 n/a November
severe psoriasis 2008
Golimumab for rheumatoid 19 Ongoing n/a Nov 2008 n/a To be
arthritis (after failure of confirmed
previous antirheumatic
drugs) -
Golimumab for rheumatoid 19 Ongoing n/a Nov 2008 n/a To be
arthritis (methotrexate- confirmed
naïve)
Golimumab for ankylosing 19 Ongoing n/a Nov 2008 n/a To be
spondylitis - confirmed
Golimumab for psoriatic 19 Ongoing n/a Nov 2008 n/a To be
arthritis confirmed
Bevacizumab in combination 19 Ongoing January Nov 2008 n/a May 2009
with oxaliplatin and either 2008
5FU or capecitabine for
colorectal cancer
(metastatic)
Dronedarone for atrial 19 Ongoing n/a Nov 2008 n/a June 09
fibrillation and atrial flutter
Erlotinib (in combination with 19 Ongoing n/a Nov 2008 n/a To be
bevacizumab) for non small confirmed
cell lung cancer (advanced or
metastatic maintenance
treatment)
Erlotinib (monotherapy) for 19 Ongoing n/a Nov 2008 n/a September
non small cell lung cancer 2009
(advanced or metastatic
maintenance treatment)
Bevacizumab, in combination 19 Ongoing n/a Nov 2008 n/a October
with non-taxane 2009
chemotherapy for breast
cancer (first line)
Temsirolimus for mantle cell 19 Ongoing n/a Nov 2008 n/a November
lymphoma (relapsed) 2009
Trabectedin for ovarian 19 Ongoing n/a Nov 2008 n/a November
cancer (relapsed) 2009
Vandetanib for non small 19 Ongoing Received Nov 2008 n/a December
cell lung cancer (second line) marketing 2009
authorisation
for stage
IIIB and IV
NSCLC in
early 2010.
Erlotinib (in combination with 19 Ongoing n/a Nov 2008 n/a To be
bevacizumab) for non small confirmed
cell lung cancer (advanced or
metastatic second line)
Sunitinib malate (in 19 Ongoing n/a March n/a January
combination with 2009 2010
capecitabine) for breast
cancer (advanced and/or
metastatic)
Sunitinib malate (in 19 Ongoing n/a March n/a January
combination with a taxane) 2009 2010
for advanced and/or
metastatic breast cancer
(first line treatment)
Trastuzumab (Herceptin) for 19 Ongoing n/a March n/a November
HER-2 positive advanced 2009 2010
gastric cancer
Rituximab for follicular non 19 Ongoing n/a March n/a August 2010
Hodgkins lymphoma 2009
(maintenance treatment
following response to first-
line chemo)
Liraglutide for diabetes 20 Ongoing n/a May 2009 n/a August 2009
mellitus (type 2) -
Denosumab (AMG-162) for 20 Ongoing n/a April 2009 n/a November
osteoporotic fractures in 2009
post-menopausal women
(prevention)
Cladribine for multiple 20 Ongoing n/a April 2009 n/a November
sclerosis 2009
(relapsing/remitting)
Ticagrelor (AZD6140) for 20 Ongoing n/a April 2009 n/a March 2010
acute coronary syndromes
Fingolimod for multiple 20 Ongoing n/a April 2009 n/a May 2010
sclerosis
(relapsing/remitting)
Fingolimod for multiple 20 Ongoing n/a April 2009 n/a To be
sclerosis (primary confirmed
progressive)
ABT-874 for chronic plaque 20 Ongoing n/a April 2009 n/a March 2011
psoriasis (moderate-to-
severe)
Everolimus for renal cell 20 Ongoing n/a November n/a July 2009
carcinoma (advanced and/or 2008
metastatic) - 2nd line
Pazopanib for renal cell 20 Ongoing n/a November n/a February
cancer (1st line advanced 2008 2010
and/or metastatic)
Pazopanib for renal cell 20 Ongoing n/a November n/a March 2010
cancer (2nd line advanced 2008
and/or metastatic)
Pemetrexed for non small 20 Ongoing n/a November n/a June 2009
cell lung cancer 2008
(maintenance)
Ipilimumab for melanoma 20 Ongoing n/a November n/a August 2010
(previously treated 2008
unresectable stage III or IV)
Ipilimumab in combination 20 Ongoing n/a November n/a August 2010
with dacarbazine for 2008
melanoma (previously
untreated unresectable stage
III or IV)
Dutasteride for prostate 20 Ongoing n/a March n/a November
cancer 2009 2009
Contusugene ladenovec for 20 Ongoing n/a March n/a March 2010
head and Neck cancer 2009
Panitumumab (in 20 Ongoing n/a March n/a June 2010
combination with 2009
chemotherapy) for colorectal
cancer (metastatic)
Nilotinib for chronic myeloid 20 Ongoing n/a March n/a August 2010
leukaemia 2009
Imatinib for gastrointestinal 21 Ongoing May 2009 April 2009 n/a September
stromal tumours (GIST) - 2009
adjuvant
Bevacizumab for 21 Ongoing n/a April 2009 n/a November
glioblastoma multiforme 2009
(relapsed)
Denosumab for therapy- 21 Ongoing n/a April 2009 n/a September
induced bone loss in non- 2009
metastatic breast cancer
Denosumab for therapy- 21 Ongoing n/a April 2009 n/a December
induced bone loss in non- 2009
metastatic prostate cancer
(1)
Date of marketing authorisation by European Medicines Agency (EMEA).
(2)
Topics before the 13th work programme were originally referred to NICE’s Multiple Technology Appraisal (MTA) programme and were
transferred to the STA programme when it was introduced in August 2006. The date provided is the date the topic was originally referred to
NICE as a Multiple Technology Appraisal.
(3)
The date NICE commenced work on the appraisal. NICE will also have carried out scoping work for the appraisal before this date.
(4)
Guidance has been reviewed since the original guidance was published. The date of final guidance and date NICE started work on the
appraisal refer to the review.
